Switch theme
Sign up to access all valuation multiples
Vitrolife AB provides medical devices and genetic testing services intended for the reproductive-health market in the field of reproductive health. The company develops, manufactures, and distributes medical devices and provides genetic testing services for IVF clinics and their patients. Its mission is to support IVF clinics (in vitro fertilization) in enhancing their practice as well as the outcome of a patientās fertility treatment, thereby enabling patients to receiveĀ support to navigate the complexities of reproductive health through successful outcomes and patient satisfaction. The group has three geographical segments EMEA, Americas and APAC, out of which it derives maximum revenue from EMEA.
1994
1.1K+
LTM Revenue $363M
LTM EBITDA $124M
$2.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Vitrolife has a last 12-month revenue of $363M and a last 12-month EBITDA of $124M.
In the most recent fiscal year, Vitrolife achieved revenue of $358M and an EBITDA of $77.8M.
Vitrolife expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Vitrolife valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $349M | $358M | XXX | XXX | XXX |
| Gross Profit | $177M | $196M | XXX | XXX | XXX |
| Gross Margin | 51% | 55% | XXX | XXX | XXX |
| EBITDA | -$317M | $77.8M | XXX | XXX | XXX |
| EBITDA Margin | -91% | 22% | XXX | XXX | XXX |
| Net Profit | $39.1M | -$382M | XXX | XXX | XXX |
| Net Margin | 11% | -107% | XXX | XXX | XXX |
| Net Debt | $155M | $112M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Vitrolife's stock price is SEK 156 (or $15).
Vitrolife has current market cap of SEK 21.1B (or $2.1B), and EV of SEK 22.0B (or $2.2B).
See Vitrolife trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.2B | $2.1B | XXX | XXX | XXX | XXX | $0.40 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Vitrolife has market cap of $2.1B and EV of $2.2B.
Vitrolife's trades at 6.0x LTM EV/Revenue multiple, and 17.6x LTM EBITDA.
Analysts estimate Vitrolife's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Vitrolife and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $2.2B | XXX | XXX | XXX |
| EV/Revenue | 6.1x | XXX | XXX | XXX |
| EV/EBITDA | 28.1x | XXX | XXX | XXX |
| P/E | 41.1x | XXX | XXX | XXX |
| P/E/Growth | 2.1x | XXX | XXX | XXX |
| EV/FCF | 24.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpVitrolife's NTM/LTM revenue growth is 6%
Vitrolife's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Vitrolife's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Vitrolife's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Vitrolife and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 3% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 22% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -125% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 28% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.3M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 21% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 13% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 3% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 38% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Vitrolife acquired XXX companies to date.
Last acquisition by Vitrolife was XXXXXXXX, XXXXX XXXXX XXXXXX . Vitrolife acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Vitrolife founded? | Vitrolife was founded in 1994. |
| Where is Vitrolife headquartered? | Vitrolife is headquartered in Sweden. |
| How many employees does Vitrolife have? | As of today, Vitrolife has 1.1K+ employees. |
| Who is the CEO of Vitrolife? | Vitrolife's CEO is Ms. Bronwyn Brophy. |
| Is Vitrolife publicy listed? | Yes, Vitrolife is a public company listed on STO. |
| What is the stock symbol of Vitrolife? | Vitrolife trades under VITR ticker. |
| When did Vitrolife go public? | Vitrolife went public in 2001. |
| Who are competitors of Vitrolife? | Similar companies to Vitrolife include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Vitrolife? | Vitrolife's current market cap is $2.1B |
| What is the current revenue of Vitrolife? | Vitrolife's last 12-month revenue is $363M. |
| What is the current EBITDA of Vitrolife? | Vitrolife's last 12-month EBITDA is $124M. |
| What is the current EV/Revenue multiple of Vitrolife? | Current revenue multiple of Vitrolife is 6.0x. |
| What is the current EV/EBITDA multiple of Vitrolife? | Current EBITDA multiple of Vitrolife is 17.6x. |
| What is the current revenue growth of Vitrolife? | Vitrolife revenue growth between 2023 and 2024 was 3%. |
| Is Vitrolife profitable? | Yes, Vitrolife is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
